FPCP
NVCR icon

Fort Point Capital Partners’s NovoCure NVCR Stock Holding History

Fort Point Capital Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,001
Closed -$232K – 294
2021
Q3 		$232K Sell
2,001
-99
-5% -$15K 0.03% 224
2021
Q2 		$466K Sell
2,100
-330
-14% -$64.2K 0.09% 107
2021
Q1 		$321K Hold
2,430
– – 0.07% 123
2020
Q4 		$420K Hold
2,430
– – 0.1% 99
2020
Q3 		$270K Buy
+2,430
New +$194K 0.07% 115

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fort Point Capital Partners's NVCR Position: Q4 2021 in Review

Fort Point Capital Partners sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 2,001 shares — an estimated $232K sold.

Fort Point Capital Partners first reported a position in NVCR in Q3 2020 and held it in 5 quarters. The position peaked at $466K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Fort Point Capital Partners reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Fort Point Capital Partners sold 2,001 NovoCure shares in Q4 2021, an estimated $232K.
  • Fort Point Capital Partners first reported a position in NovoCure in Q3 2020 and held it in 5 quarters.
  • Fort Point Capital Partners's NovoCure position peaked at $466K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Fort Point Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.